MedTrace Logo

Meu-cinn for Gastric Mucosal Health in Adults With Functional Dyspepsia

NCT06630455 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-06-03

No results posted yet for this study

Summary

This clinical trial aims to determine whether Meu-cinn promotes gastric mucosal health in adults with functional dyspepsia and to assess its safety.

The main questions are:

* Does Meu-cinn promote gastric mucosal health in participants?
* What side effects occur when participants take Meu-cinn?

Conditions

  • Functioanl Dyspepsia

Interventions

DIETARY_SUPPLEMENT

Meu-cinn

Meu-cinn 250 mg/day for 8 weeks

DIETARY_SUPPLEMENT

Placebo

Placebo 250 mg/day for 8 weeks

Sponsors & Collaborators

  • Pusan National University Yangsan Hospital

    lead OTHER

Principal Investigators

  • Sang Yeoup Lee, Professor, MD, PhD · Pusan National University Yangsan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-04
Primary Completion
2025-12-30
Completion
2025-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06630455 on ClinicalTrials.gov